Glenn Miller, Ph.D., Joins MolecularMD as Chief Technology Officer and Executive Vice President
August 08, 2013 08:05 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Aug 8, 2013) - MolecularMD Corporation today announced that Dr. Glenn Miller has been appointed to the executive management team as Chief Technology Officer and...
MolecularMD Corp. Obtains License to Commercialize Predictive Diagnostic Based on Actionable Biomarker, DDR2, for Uses in Lung Cancer and Targeted Kinase Therapy
July 29, 2013 08:05 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Jul 29, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD Corp. Obtains Exclusive License to Uses of FGFR2 Activating Mutations in Endometrial Cancer
May 30, 2013 08:10 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - May 30, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD Corp. Offers Testing Services for Determining LKB1 Mutation and Expression Status
April 09, 2013 08:15 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Apr 9, 2013) - MolecularMD Corp. announced today that it has developed and clinically validated assays for determining LKB1 mutation and expression status in patient...
MolecularMD Announces Launch of Next Generation Sequencing Services for Oncology Drug Development
April 04, 2013 07:45 ET
|
MolecularMD
PORTLAND, OR--(Marketwired - Apr 4, 2013) - Today MolecularMD Corp. announced the launch of its next generation sequencing (NGS) services designed to support MolecularMD's pharmaceutical and...
MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer
January 28, 2013 08:30 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...
MolecularMD and Ventana Medical Systems, Inc. Reach Collaborative Research Agreement: Limits of Detection and Sensitivity for PTEN Gene Using In-Situ Hybridization and Immunohistochemistry Methods
December 06, 2012 11:41 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Dec 6, 2012) - MolecularMD, based in Portland, OR, has formed a collaborative research agreement with Ventana Medical Systems, Inc. (Ventana), a member of the Roche...
MolecularMD Announces Next Generation Sequencing Presentation at Upcoming American Society of Hematology Annual Meeting
December 06, 2012 11:31 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Dec 6, 2012) - MolecularMD Corp. announced today that it will present data at the annual meeting of the American Society of Hematology conference, pertaining to the...
MolecularMD Announces Three Presentations Highlighting Non-Invasive Biomarker Detection and NGS Validation at Upcoming Scientific Conferences
October 24, 2012 08:00 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Oct 24, 2012) - MolecularMD Corp. announced today that presentations pertaining to clinical validation of Next Generation Sequencing platforms and advances in...
MolecularMD Submits Premarketing Approval Application to the FDA for Its BCR-ABL T315I Mutation Test, a Companion Diagnostic to Ponatinib, an Investigational BCR-ABL Inhibitor
July 30, 2012 16:05 ET
|
MolecularMD
PORTLAND, OR--(Marketwire - Jul 30, 2012) - MolecularMD Corp. today announced that it has submitted its application for Premarket Approval (PMA) of the MolecularMD BCR-ABL T315I Mutation Test...